相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular Signaling Pathways and Essential Metabolic Elements in Bone Remodeling: An Implication of Therapeutic Targets for Bone Diseases
Aditi Sharma et al.
CURRENT DRUG TARGETS (2021)
Anlotinib as a molecular targeted therapy for tumors
Yi Gao et al.
ONCOLOGY LETTERS (2020)
Magnoflorine Suppresses MAPK and NF-κB Signaling to Prevent Inflammatory Osteolysis Induced by Titanium Particles In Vivo and Osteoclastogenesis via RANKL In Vitro
Zhenyu Sun et al.
FRONTIERS IN PHARMACOLOGY (2020)
Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies
Ingrid Lilienthal et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Integrated analysis of transcriptome-wide m6A methylome of osteosarcoma stem cells enriched by chemotherapy
Yongjie Wang et al.
EPIGENOMICS (2019)
Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases
Di Wang et al.
CANCER RESEARCH (2019)
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study
Sant Chawla et al.
LANCET ONCOLOGY (2019)
Molecular targeted therapy: Treating cancer with specificity
Yeuan Ting Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
Patrick Schoffski et al.
BREAST CANCER RESEARCH (2018)
correlation analysis between tumor imaging changes and p-AKT and HSP70 expression in tumor cells after osteosarcoma chemotherapy
Feng Ji et al.
ONCOLOGY LETTERS (2017)
Monocytes, Macrophages, and Osteoclasts in Osteosarcoma
Fergal C. Kelleher et al.
JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY (2017)
The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer
Shu-Xiong Zeng et al.
CLINICAL CANCER RESEARCH (2017)
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma
Yun-Rong Zhu et al.
CANCER BIOLOGY & THERAPY (2015)
Bone microenvironment signals in osteosarcoma development
Arantzazu Alfranca et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
PI3K/Akt signaling in osteosarcoma
Jian Zhang et al.
CLINICA CHIMICA ACTA (2015)
The PI3K/AKT cell signaling pathway is involved in regulation of osteoporosis
Jian-Cheng Xi et al.
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION (2015)
Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy
Marieke L. Kuijjer et al.
BMC MEDICAL GENOMICS (2014)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate
Berengere Gobin et al.
CANCER LETTERS (2014)
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma
Jennifer A. Perry et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis
Liliana Endo-Munoz et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2012)
Akt Induces Osteoclast Differentiation through Regulating the GSK3 beta/NFATc1 Signaling Cascade
Jang Bae Moon et al.
JOURNAL OF IMMUNOLOGY (2012)
New insights into osteoclastogenic signaling mechanisms
Tomoki Nakashima et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2012)
Therapeutic Approach of Primary Bone Tumours by Bisphosphonates
G. Moriceau et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Osteosarcoma Incidence and Survival Rates From 1973 to 2004 Data From the Surveillance, Epidemiology, and End Results Program
Lisa Mirabello et al.
CANCER (2009)
Osteosarcoma development and stem cell differentiation
Ni Tang et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2008)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Increased osteoclast activity is associated with aggressiveness of osteosarcoma
Sofia Avnet et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2008)
Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: Blockade of the vicious cycle between tumor cell proliferation and bone resorption
Francois Lamoureux et al.
CANCER RESEARCH (2007)
Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation
LC Foukas et al.
NATURE (2006)
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma
D Heymann et al.
BONE (2005)
分享论文
